WS #16020
The biotech sector is facing renewed regulatory headwinds as Omeros receives a negative opinion from the EMA's CHMP regarding its marketing authorization for narsoplimab, causing shares to trade lower. Similarly, GUTS saw its valuation halved after positive REMAIN-1 data failed to support the company's higher growth assumptions, underscoring the market's increasing intolerance for modest effect sizes in clinical trials.
Biotech Regulatory Setbacks
The biotech sector is facing renewed regulatory headwinds as Omeros receives a negative opinion from the EMA's CHMP regarding its marketing authorization for narsoplimab, causing shares to trade lower. Similarly, GUTS saw its valuation halved after positive REMAIN-1 data failed to support the company's higher growth assumptions, underscoring the market's increasing intolerance for modest effect sizes in clinical trials.